Geographic variation in the utilisation of specialist healthcare for patients with severe mental illness in Norway: a population-based registry study.

Purpose: The aim of this study is to measure geographic variations in mental healthcare service utilisation among patients with severe mental illness in Norway.

Method: We analysed data from the Norwegian patient registry for 2014-2018 for patients with severe mental illness. The outcomes measured in this study were: outpatient contact, admission, bed days and total contact rates.

Geographical variation in orthopedic procedures in Norway: Cross-sectional population-based study.

Background: Standardized surgery rates for common orthopedic procedures vary across geographical areas in Norway. We explored whether area-level factors related to demand and supply in publicly funded healthcare are associated with geographical variation in surgery rates for six common orthopedic procedures.

Methods: The present study is a cross-sectional population-based study of hospital referral areas in Norway.

Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study.

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a disease with high symptom burden, of unknown etiology, with no established treatment. We observed patients with long-standing ME/CFS who got cancer, and who reported improvement of ME/CFS symptoms after chemotherapy including cyclophosphamide, forming the basis for this prospective trial. This open-label phase II trial included 40 patients with ME/CFS diagnosed by Canadian criteria.

Albumin and bleed risk in rivaroxaban treated patients.

Drugs exhibiting high protein binding have potential increased action in patients with hypoalbuminemia. Rivaroxaban is 92-95% protein bound, but the clinical effects of rivaroxaban in patients with low albumin are largely unknown. The purpose of this study was to evaluate the relationship between albumin and bleeding in rivaroxaban treated patients.

Clinical outcomes following treatment of Enterobacter species pneumonia with piperacillin/tazobactam compared to cefepime or ertapenem.

Background: Enterobacter spp. are a common cause of nosocomial pneumonia and treatment can be complicated by AmpC resistance. Carbapenems are the treatment of choice; however, alternatives are needed.